DNDi is sourcing a CDMO for formulation activities leading to commercialisable tablet formulation, followed by GMP manufacturing and packaging of clinical supplies to support the Phase Ib and II trials targeting visceral leishmaniasis.

DNDi is sourcing a CRO offering Data Management, Biostatistics, and IRT Services for one of our clinical trial targeting visceral leishmaniasis.

DNDi is currently sourcing a CRO able to perform a CTA enabling package for one compound targeting visceral leishmaniasis.

DNDi is seeking a CDMO/partner to play a major role in improving the API process of a novel DNDi compound that will enable the realization of low production costs.

DNDi is sourcing a Contract Development and Manufacturing Organization (CDMO) offering an integrated platform of pharmaceutical development and manufacturing capabilities to cover Drug Substance and Drug Product activities of a compound targeting onchocerciasis.